Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Zika Virus Clear all
Completed Phase 1 Interventional

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

NCT02840487
View directory record Official record
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA085-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 6, 2026, 4:52 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Neurodevelopmental Outcomes in ZIKV-Exposed Children

NCT04398901
View directory record Official record
Conditions
Zika Virus, Congenital Zika Syndrome, Congenital Infection, Child Development
Interventions
Neurodevelopmental assessments
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 7 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Completed No phase listed Observational

Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

NCT02794181
View directory record Official record
Conditions
Zika Virus, Dengue Virus, Chikungunya Virus Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 6, 2026, 4:52 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

NCT05469802
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Purified Inactivated Zika Virus Vaccine (PIZV), Placebo
Biological · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
5
States / cities
Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

NCT03014089
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1325, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

NCT03641339
View directory record Official record
Conditions
Zika, Dengue, Malaria, Chikungunya, Leishmaniasis
Interventions
One vector feeding, Four vector feeding
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

NCT02996461
View directory record Official record
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA090-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 6, 2026, 4:52 PM EDT
Enrolling by invitation No phase listed Observational

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07520279
View directory record Official record
Conditions
Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions
Xpert Tropical Fever test
Diagnostic Test
Lead sponsor
Cepheid
Industry
Eligibility
14 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ZIKA Vaccine in Naive Subjects

NCT02952833
View directory record Official record
Conditions
Zika Virus Infection
Interventions
Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)

NCT05123222
View directory record Official record
Conditions
Zika Virus
Interventions
ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 6, 2026, 4:52 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

NCT01386424
View directory record Official record
Conditions
Zika, Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA

NCT03776903
View directory record Official record
Conditions
Zika Virus Infection
Interventions
ZIKV Detect™ 2.0 IgM Capture ELISA
Other
Lead sponsor
InBios International, Inc.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

NCT04064905
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Omaha, Nebraska • Austin, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

NCT06334393
View directory record Official record
Conditions
Zika, Zika Virus Infection
Interventions
VLA1601, CpG 1018®, 3M-052-AF
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626
View directory record Official record
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 6, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parental Views Related to Colorado State Legislation About Vaccinations, Schools, and Child Care Centers

NCT02957344
View directory record Official record
Conditions
Healthy Children
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
679 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

NCT03611946
View directory record Official record
Conditions
Zika Virus
Interventions
Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

NCT03425149
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection
Interventions
VLA1601, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GLS-5700 in Dengue Virus-Naïve Adults

NCT02809443
View directory record Official record
Conditions
Healthy
Interventions
GLS-5700
Biological
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Cohort Study of HIV and Zika in Infants and Pregnancy

NCT03263195
View directory record Official record
Conditions
HIV, Zika Virus, Pregnant Women
Interventions
Not listed
Lead sponsor
Westat
Other
Eligibility
15 Years and older · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Miami, Florida • The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 6, 2026, 4:52 PM EDT
Active, not recruiting Phase 3 Interventional

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 6, 2026, 4:52 PM EDT